佛慈制藥(002644.SZ)擬斥3000萬元設立全資子公司
格隆匯11月22日丨佛慈制藥(002644.SZ)公佈,根據公司業務規劃和經營發展需要,公司以自有資金投資設立全資子公司蘭州佛慈科創有限公司(暫定,以市場監督管理部門核准登記為準,“佛慈科創公司”),註冊資本人民幣3000萬元。
蘭州佛慈科創有限公司經營範圍:管理中醫藥產業相關載體,提供以中成藥、西藥、生物技術、中藥飲片、中藥配方顆粒、特殊醫學用途配方食品、保健食品、醫療器械等產品的研發、生產、批發、零售及檢測服務;中藥材種植、收購、加工、銷售;生物科技、食品、藥品專業領域內的技術開發、技術諮詢、技術服務、技術轉讓、電子商務(不得從事增值電信業務);健康信息諮詢;養生諮詢,養生技術及產品研發;預包裝食品;中醫藥品、保健品研發及相關技術諮詢服務;自營和代理各類商品和技術進出口(國家限制和禁止的項目除外)。
公司擁有藥品批准文號467個,目前常規生產有130多個,未發揮出應有的經濟效益。基於公司藥品批准文號資源及生產、質量、技術、檢測等配套能力,我公司投資設立佛慈科創公司,以公司藥品批准文號和佛慈品牌進行招商,引入具有銷售渠道和能力的合作伙伴,激活閒置藥品批准文號,實現藥品批准文號資源整合共享,促進上下游企業的分工協作,形成完整的中醫藥產業鏈,促進中醫藥產學研合作、協同創新,加速科技成果轉化,形成產業配套能力,進一步提升公司盈利能力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.